STAT+: Fibrogen’s data manipulation scandal came with questions. There need to be answers
Fibrogen is reeling from the worst case of data manipulation in years, but six weeks after the scandal broke, the drug maker still hasn’t explained why or how it happened, or identify the people responsible.
On a conference call Monday, Fibrogen CEO Enrique Conterno reiterated his “confidence” in the drug maker’s experimental anemia treatment, a pill called roxadustat. But how can anyone — investors, physicians, regulators – trust a company that spent nearly two years touting cardiovascular safety data that turns out to have been falsified?
